About Anika Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://anika.com/
Frequently Asked Questions
What is the 52-week range for ANIK?
The 52-week high is $22.88 and the 52-week low is $8.67.
What is the P/E ratio for ANIK?
The P/E ratio data is currently unavailable.
What is the dividend yield for ANIK?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -2.70%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -3.14%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.97.
Analyst Recommendation Trends
Wall Street analyst consensus for ANIK over the last few months:
Latest ANIK News
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23
B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.
Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Teva's TEV '408 meets its phase IIa celiac disease goal, preventing gluten-induced intestinal damage and showing a favorable safety profile.
QURE Submits Application for Gene Therapy for Huntington's Disease
QURE seeks accelerated FDA approval for AMT-130, with Priority Review and a U.K. filing adding momentum to its regulatory push.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-04 | Fischetti Gary P | +1,000 | $20.315 | $20,315 |
| 2026-08-03 | Fischetti Gary P | +1,000 | $20.745 | $20,745 |
| 2026-06-18 | Fischetti Gary P | +10,402 | - | - |
| 2026-06-18 | Richard Stephen | +10,402 | - | - |
| 2026-06-18 | Capper Joseph H | +10,402 | - | - |
| 2026-06-18 | CONLEY SHERYL L | +10,402 | - | - |
| 2026-06-18 | HENNEMAN JOHN B III | +10,402 | - | - |
| 2026-06-03 | Griffin Stephen D. | -12,840 | - | - |
| 2026-06-03 | Griffin Stephen D. | -3,769 | $14.41 | $54,311 |
| 2026-06-03 | Griffin Stephen D. | +12,840 | - | - |
| 2026-05-01 | HENNEMAN JOHN B III | +5,000 | $14.6639 | $73,320 |
| 2026-04-30 | Griffin Stephen D. | +12,200 | $12.2853 | $149,881 |
| 2026-03-19 | McLeod Ian | +17,663 | - | - |
| 2026-03-19 | McLeod Ian | +11,194 | - | - |
| 2026-03-19 | McLeod Ian | +13,097 | - | - |
| 2026-03-15 | Colleran David | -6,449 | - | - |
| 2026-03-15 | Colleran David | -1,893 | $14.2 | $26,881 |
| 2026-03-15 | Colleran David | +6,449 | - | - |
| 2026-03-15 | McLeod Ian | -2,658 | - | - |
| 2026-03-15 | McLeod Ian | -781 | $14.2 | $11,090 |
| 2026-03-15 | McLeod Ian | +2,658 | - | - |
| 2026-03-15 | Blanchard Cheryl R | -25,131 | - | - |
| 2026-03-15 | Blanchard Cheryl R | -12,104 | $14.2 | $171,877 |
| 2026-03-15 | Blanchard Cheryl R | +25,131 | - | - |
| 2026-03-14 | Griffin Stephen D. | -12,824 | - | - |
| 2026-03-14 | Griffin Stephen D. | -5,944 | $14.2 | $84,405 |
| 2026-03-14 | Griffin Stephen D. | +6,412 | - | - |
| 2026-03-14 | Griffin Stephen D. | +12,824 | - | - |
| 2026-03-14 | Colleran David | -9,388 | - | - |
| 2026-03-14 | Colleran David | -4,168 | $14.2 | $59,186 |
| 2026-03-14 | Colleran David | +4,694 | - | - |
| 2026-03-14 | Colleran David | +9,388 | - | - |
| 2026-03-14 | McLeod Ian | -3,774 | - | - |
| 2026-03-14 | McLeod Ian | -1,449 | $14.2 | $20,576 |
| 2026-03-14 | McLeod Ian | +1,161 | - | - |
| 2026-03-14 | McLeod Ian | +3,774 | - | - |
| 2026-03-14 | Blanchard Cheryl R | -24,519 | - | - |
| 2026-03-14 | Blanchard Cheryl R | -14,728 | $14.2 | $209,138 |
| 2026-03-14 | Blanchard Cheryl R | +24,520 | - | - |
| 2026-03-14 | Blanchard Cheryl R | +24,519 | - | - |
| 2026-03-09 | Colleran David | -5,465 | - | - |
| 2026-03-09 | Colleran David | -1,919 | $14.96 | $28,708 |
| 2026-03-09 | Colleran David | +5,465 | - | - |
| 2026-03-09 | McLeod Ian | -2,197 | - | - |
| 2026-03-09 | McLeod Ian | -639 | $14.96 | $9,559 |
| 2026-03-09 | McLeod Ian | +2,197 | - | - |
| 2026-03-09 | Blanchard Cheryl R | -20,001 | - | - |
| 2026-03-09 | Blanchard Cheryl R | -5,871 | $14.96 | $87,830 |
| 2026-03-09 | Blanchard Cheryl R | +20,001 | - | - |
| 2026-02-01 | Griffin Stephen D. | +130,402 | - | - |
| 2026-02-01 | Griffin Stephen D. | +310,207 | - | - |